Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study

J. Krischer, V. J. Land, C. I. Civin, A. H. Ragab, D. H. Mahoney, L. S. Frankel

Research output: Contribution to journalArticle

Abstract

One hundred four children with advanced leukemia in relapse (74 with acute lymphocytic leukemia [ALL] and 30 with acute nonlymphocytic leukemia [ANLL]) received AMSA (4'-(9-Acridinyl-amino)methanesulfon-m-anisidide) at a dose of 120 mg/m2/day for 5 days (Regimen I) or 60 mg/m2/day for 10 days (Regimen II). Children with ALL were randomized between Regimens I and II (31 and 36 evaluable patients, respectively). All 29 evaluable patients with ANLL were treated on Regimen I. Eighty-eight percent of evaluable patients experienced severe or life-threatening toxicity, with no statistical differences between Regimens I and II. Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL. Fatal cardiac toxicity occurred in one patient. Complete or partial response occurred in 25.0% (SE = 8.8%), 28.1% (SE = 8.0%), and 25.9% (SE = 8.4%) of evaluable patients on ALL Regimen I, ALL Regimen II, and ANLL, respectively. However, responses were of short duration (16-91 days). There was no significant difference in the duration of survival from treatment start for the two ALL Regimens (P = 0.46). The median duration of survival for ANLL patients was significantly longer (P = 0.004) than that of ALL patients treated on Regimens I and II combined. Eighty-two percent of the complete or partial responses (18 of 22) occurred after the first course of AMSA. At the dose schedules investigated, and in a heavily pretreated patient population, AMSA had activity in childhood leukemia. However, the high incidence of severe, life-threatening, or fatal infections meant that the quality and quantity of responses and survival was not commensurate with the toxicity, and that it would be difficult to incorporate this drug into combination chemotherapy with other myelosuppressive agents.

Original languageEnglish (US)
Pages (from-to)207-210
Number of pages4
JournalCancer
Volume54
Issue number2
StatePublished - 1984

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Pediatrics
Acute Myeloid Leukemia
Survival
Mycoses
Drug Combinations
Combination Drug Therapy
Bacterial Infections
Appointments and Schedules
Recurrence
Incidence
Infection
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Krischer, J., Land, V. J., Civin, C. I., Ragab, A. H., Mahoney, D. H., & Frankel, L. S. (1984). Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study. Cancer, 54(2), 207-210.

Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study. / Krischer, J.; Land, V. J.; Civin, C. I.; Ragab, A. H.; Mahoney, D. H.; Frankel, L. S.

In: Cancer, Vol. 54, No. 2, 1984, p. 207-210.

Research output: Contribution to journalArticle

Krischer, J, Land, VJ, Civin, CI, Ragab, AH, Mahoney, DH & Frankel, LS 1984, 'Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study', Cancer, vol. 54, no. 2, pp. 207-210.
Krischer J, Land VJ, Civin CI, Ragab AH, Mahoney DH, Frankel LS. Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study. Cancer. 1984;54(2):207-210.
Krischer, J. ; Land, V. J. ; Civin, C. I. ; Ragab, A. H. ; Mahoney, D. H. ; Frankel, L. S. / Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study. In: Cancer. 1984 ; Vol. 54, No. 2. pp. 207-210.
@article{182119f9a0f2429f9d0676adec195b7f,
title = "Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study",
abstract = "One hundred four children with advanced leukemia in relapse (74 with acute lymphocytic leukemia [ALL] and 30 with acute nonlymphocytic leukemia [ANLL]) received AMSA (4'-(9-Acridinyl-amino)methanesulfon-m-anisidide) at a dose of 120 mg/m2/day for 5 days (Regimen I) or 60 mg/m2/day for 10 days (Regimen II). Children with ALL were randomized between Regimens I and II (31 and 36 evaluable patients, respectively). All 29 evaluable patients with ANLL were treated on Regimen I. Eighty-eight percent of evaluable patients experienced severe or life-threatening toxicity, with no statistical differences between Regimens I and II. Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL. Fatal cardiac toxicity occurred in one patient. Complete or partial response occurred in 25.0{\%} (SE = 8.8{\%}), 28.1{\%} (SE = 8.0{\%}), and 25.9{\%} (SE = 8.4{\%}) of evaluable patients on ALL Regimen I, ALL Regimen II, and ANLL, respectively. However, responses were of short duration (16-91 days). There was no significant difference in the duration of survival from treatment start for the two ALL Regimens (P = 0.46). The median duration of survival for ANLL patients was significantly longer (P = 0.004) than that of ALL patients treated on Regimens I and II combined. Eighty-two percent of the complete or partial responses (18 of 22) occurred after the first course of AMSA. At the dose schedules investigated, and in a heavily pretreated patient population, AMSA had activity in childhood leukemia. However, the high incidence of severe, life-threatening, or fatal infections meant that the quality and quantity of responses and survival was not commensurate with the toxicity, and that it would be difficult to incorporate this drug into combination chemotherapy with other myelosuppressive agents.",
author = "J. Krischer and Land, {V. J.} and Civin, {C. I.} and Ragab, {A. H.} and Mahoney, {D. H.} and Frankel, {L. S.}",
year = "1984",
language = "English (US)",
volume = "54",
pages = "207--210",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluation of AMSA in children with acute leukemia. A pediatric oncology group study

AU - Krischer, J.

AU - Land, V. J.

AU - Civin, C. I.

AU - Ragab, A. H.

AU - Mahoney, D. H.

AU - Frankel, L. S.

PY - 1984

Y1 - 1984

N2 - One hundred four children with advanced leukemia in relapse (74 with acute lymphocytic leukemia [ALL] and 30 with acute nonlymphocytic leukemia [ANLL]) received AMSA (4'-(9-Acridinyl-amino)methanesulfon-m-anisidide) at a dose of 120 mg/m2/day for 5 days (Regimen I) or 60 mg/m2/day for 10 days (Regimen II). Children with ALL were randomized between Regimens I and II (31 and 36 evaluable patients, respectively). All 29 evaluable patients with ANLL were treated on Regimen I. Eighty-eight percent of evaluable patients experienced severe or life-threatening toxicity, with no statistical differences between Regimens I and II. Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL. Fatal cardiac toxicity occurred in one patient. Complete or partial response occurred in 25.0% (SE = 8.8%), 28.1% (SE = 8.0%), and 25.9% (SE = 8.4%) of evaluable patients on ALL Regimen I, ALL Regimen II, and ANLL, respectively. However, responses were of short duration (16-91 days). There was no significant difference in the duration of survival from treatment start for the two ALL Regimens (P = 0.46). The median duration of survival for ANLL patients was significantly longer (P = 0.004) than that of ALL patients treated on Regimens I and II combined. Eighty-two percent of the complete or partial responses (18 of 22) occurred after the first course of AMSA. At the dose schedules investigated, and in a heavily pretreated patient population, AMSA had activity in childhood leukemia. However, the high incidence of severe, life-threatening, or fatal infections meant that the quality and quantity of responses and survival was not commensurate with the toxicity, and that it would be difficult to incorporate this drug into combination chemotherapy with other myelosuppressive agents.

AB - One hundred four children with advanced leukemia in relapse (74 with acute lymphocytic leukemia [ALL] and 30 with acute nonlymphocytic leukemia [ANLL]) received AMSA (4'-(9-Acridinyl-amino)methanesulfon-m-anisidide) at a dose of 120 mg/m2/day for 5 days (Regimen I) or 60 mg/m2/day for 10 days (Regimen II). Children with ALL were randomized between Regimens I and II (31 and 36 evaluable patients, respectively). All 29 evaluable patients with ANLL were treated on Regimen I. Eighty-eight percent of evaluable patients experienced severe or life-threatening toxicity, with no statistical differences between Regimens I and II. Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL. Fatal cardiac toxicity occurred in one patient. Complete or partial response occurred in 25.0% (SE = 8.8%), 28.1% (SE = 8.0%), and 25.9% (SE = 8.4%) of evaluable patients on ALL Regimen I, ALL Regimen II, and ANLL, respectively. However, responses were of short duration (16-91 days). There was no significant difference in the duration of survival from treatment start for the two ALL Regimens (P = 0.46). The median duration of survival for ANLL patients was significantly longer (P = 0.004) than that of ALL patients treated on Regimens I and II combined. Eighty-two percent of the complete or partial responses (18 of 22) occurred after the first course of AMSA. At the dose schedules investigated, and in a heavily pretreated patient population, AMSA had activity in childhood leukemia. However, the high incidence of severe, life-threatening, or fatal infections meant that the quality and quantity of responses and survival was not commensurate with the toxicity, and that it would be difficult to incorporate this drug into combination chemotherapy with other myelosuppressive agents.

UR - http://www.scopus.com/inward/record.url?scp=0021234769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021234769&partnerID=8YFLogxK

M3 - Article

C2 - 6586277

AN - SCOPUS:0021234769

VL - 54

SP - 207

EP - 210

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -